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Frequencies of the T-455C and C-482T 
apoCIII gene polymorphisms in different 
South African population groups and their 
relationship to fasting serum triglyceride levels
The gene encoding apoCIII lies on the long arm of chromosome 11 
(11q23-qter) within a cluster of related genes (apoAI, apoCIII, 
apoAIV and apoAV) that function in the control of lipid meta-
bolism.(7) Fibrates have been shown to reduce serum triglyceride 
levels by inhibiting apoCIII gene transcription. This effect occurs 
through activation of the peroxisome proliferator-activated recep-
tor (PPAR)-α which in turn leads to transcriptional repression of 
hepatocyte nuclear factor (HNF)-4α, 8 a transcription factor that 
is necessary for apoCIII gene transcription.  
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TRIGLYCERIDE 
LEVELS  AND APOCIII 
POLYMORPHISMS
INTRODUCTION                                                                     
Apolipoprotein CIII (apoCIII), is an essential constituent of very 
low density lipoprotein (VLDL), high density lipoprotein (HDL) 
and chylomicrons and has been shown to be an important regu-
lator of intravascular triglyceride metabolism through the inhibi-
tion of lipoprotein lipase and interference with apoE mediated 
triglyceride–rich lipoprotein uptake by hepatic receptors.(1) In-
vitro and transgenic animal studies have demonstrated that over-
expression of apoCIII causes delayed clearance of triglyceride 
rich lipoproteins from plasma resulting in overt hypertriglyceri-
daemia.(2) Furthermore, the results from a large clinical study 
have indicated that apoCIII levels were better predictors of risk 
for the development and progression of CAD than traditionally 
measured serum triglyceride levels.(3) Recent interest has focused 
on the possible involvement of genetic variations in genes regulating 
lipid metabolism in causing hyperlipidaemia(4-6) and thus predis-
posing to CAD. The gene encoding apoCIII is therefore an 
obvious candidate gene for dyslipidaemia.
Studies have demonstrated that serum triglyceride levels are 
higher in Indian and White than Black South African subjects. 
Polymorphisms in the apoCIII gene have been associated 
with raised triglyceride levels. This study investigated the 
prevalence of apoCIII polymorphisms and their effect on 
triglyceride levels in three South African population groups 
and in subjects with fasting hypertriglyceridaemia (HT). 
Two apoCIII polymorphic sites (T-455C and C-482T) were 
studied in 78 European, 24 Indian and 25 African subjects. 
Each ethnic group included HT and non-HT (control) 
patients. Although triglyceride levels were much higher in 
the HT subjects, no signifi cant differences were noted 
between the groups for allele or genotype frequencies at 
either apoCIII locus. Furthermore, at neither locus was 
there an association between the genotype and serum 
triglyceride levels. The HT and control subjects were there-
fore combined and ethnic differences in allele frequencies 
were investigated. The African subjects had a higher 
frequency (0.79) of the unfavourable C allele at position 455 
than both Indian (0.56; p<0.05) and European (0.41; 
p<0.0005) subjects. Furthermore, African subjects had a 
higher frequency (0.77) of the unfavourable T allele at 
locus 482 than Indian (0.44, p<0.005) and European (0.36, 
p<0.0005) subjects despite triglyceride levels being lower 
in the African (0.60 [1.60] mmol/l) than European (0.90 
[0.40] mmol/l; p<0.05) control subjects. These results 
suggest that the apoCIII polymorphisms studied do not 
contribute to the raised triglyceride levels in HT subjects and 
do not explain the ethnic differences observed in fasting 



















Various studies have shown that hyperlipidaemia and particularly 
hypertriglyceridaemia may have a genetic predisposition, but 
the genes responsible have not yet been fully elucidated.(9-11) 
Olivieri and co-workers,(5) identifi ed apoCIII polymorphisms that 
are believed to play an important role in the metabolism of 
circulating triglyceride rich lipoproteins. Several variant alleles of 
the apoCIII gene have been investigated as possible genetic 
markers of hypertriglyceridaemia.(12) Two polymorphic nucleotides 
located at positions -455 (T to C) and -482 (C to T) in the 5’ 
apoCIII promoter region have been associated with elevated 
plasma triglyceride levels.(5) 
In South Africa, dyslipidaemia and CAD are far more common in 
the Indian and European than African populations.(13-15) Further-
more, Indians have been shown to exhibit a higher prevalence of 
the metabolic syndrome and CAD when compared to other 
ethnic groups, worldwide.(16) Therefore, the aims of the current 
study were to determine the frequencies of the apoCIII T-455C 
and C-482T polymorphisms and observe their effects on serum 
triglyceride concentrations in African, Indian and European South 
African subjects with and without raised fasting triglyceride levels.  
MATERIALS AND METHODS                                                 
Subjects
A total of 78 (47 males) European, 24 (6 males) Indian and 25 
(6 males) African subjects were included in the study. This total 
cohort consisted of those with a fasting triglyceride level > 3mmol/l 
and a group of control subjects. Newly diagnosed hyper-
triglyceridaemia (HT) patients who had not previously received 
any lipid lowering agents were recruited from the lipid clinic of 
the Johannesburg Hospital with a fasting serum triglyceride cut-
off value of > 3mmol/l used as a selection criteria. This group 
comprised of 57 European, 10 Indian and 4 African individuals. 
Control, healthy subjects with no history of diabetes, cardiovas-
cular disease or dyslipidaemia was recruited to the study via 
advertisement and included 21 European, 14 Indian and 21 African 
subjects. The study was explained to the volunteers and written 
informed consent obtained. The investigation was approved by 
the University of Witwatersrand Ethics committee.
Biochemical measurements
All blood samples were taken from subjects after an overnight 
fast of not less than 10 hours.  Total serum cholesterol concentra-
tions were determined by an enzymatic method (CHOD-
PAP, Roche Diagnostics, Mannheim, Germany), as were trigly-
ceride concentrations (GOD-PAP, Roche Diagnostics, Mannheim, 
Germany). High density lipoprotein-cholesterol (HDL-C) was 
determined using the HDL-C Plus Third Generation Assay (Roche 
Diagnostics, Mannheim, Germany). This is a homogeneous assay 
in which cholesterol esterase and cholesterol oxidase enzymes 
are conjugated to polyethyleneglycol to enhance the specifi city 
of the assay to HDL-C thus reducing cross reaction with choles-
terol in the LDL particles. Fasting blood glucose levels were 
determined by a glucose oxidase method (glucose GOD-PAP, 
Boehringer Mannheim) using a Hitachi 717 auto-analyser.  Diabetes 
was defi ned as a fasting glucose >7mmol/l in subjects who were 
diagnosed with the disease during the course of the study whilst 
pre-diagnosed diabetics were defi ned as such according to the 
use of oral anti-diabetic agents or insulin injections.
Genotyping
Genomic DNA was extracted using a salting-out method.(17) The 
apoCIII -455 (T to C) and -482 (C to T) polymorphisms were 
detected using restriction fragment length polymorphism based 
polymerase chain reaction.(5) Each PCR reaction contained 100ng 
genomic DNA with PCR buffer containing 1.5mM MgCl2, 3.2 mM of 
dATP, dCTP, dGTP, dTTP, the two primers (10pmol) and 1 unit of 
Taq polymerase in a 50μl reaction. The PCR reaction was initiated 
at 94°C for 5min, thereafter 35 temperature cycles of 94ºC for 
60sec, 60ºC for 60sec and 72ºC for 60 sec, was carried out.  A fi nal 
elongation step at 72°C for 10 min was performed to ensure 
maximum product yield. The primers used have been described 
previously:(11) forward primer, 5’-ACAGGTTAATATAGTGAAAAG-
3’ and reverse primer 5’-TACCCTGAGTTCAGTTCCGTC-3’. 
The PCR products (10μl) were digested in two separate reaction 
tubes using the endonuclease restriction enzymes Fok I for T-455C 
and MSP I for C-482T at 37ºC for 2 hours. The DNA fragments 
were separated on a 2% agarose gel and the bands visualised under 
300nm ultraviolet trans-illumination after staining with ethidium 
bromide.  The restriction enzyme Fok I cleaves the -455 wild type T 
allele and appears as two bands on the gel electrophoresis (133bp 
and 129bp), and the variant C allele appears as a single 196bp 
fragment. The -482 wild type C allele is cleaved by Msp I and 
appears as a 143bp band and the variant as a 159bp band.
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Statistical analysis
Data that was not normally distributed was transformed by taking 
log or reciprocal values for use in parametric statistical tests. 
The differences in lipid levels between patients and control 
subjects were analysed using analysis of co-variance (ANCOVA) 
with adjustment for age, gender and ethnicity. Lipid levels were 
compared across ethnic groups using ANCOVA adjusted for age, 
gender and diabetes whilst lipid levels were compared across 
genotypes using ANCOVA adjusted for age, gender, ethnicity and 
diabetes. A 2 test was used to analyse the frequency of the dif-
ferent polymorphisms. Data in the text and tables is expressed 
as median [interquartile range] or mean ± SD.
RESULTS                                                                                   
Lipid levels in study groups
The hypertriglyceridaemic (HT) patients were older (48.7 ± 11.1 
vs. 36.5 ± 9.6 years; p<0.0005) and had higher fasting serum 
triglyceride (10.8 [11.5] vs. 0.86 [0.44] mmol/l; p<0.0005) and 
total cholesterol levels (8.10 [3.50] vs. 4.55 [0.99] mmol/l; 
p<0.0005) but lower fasting serum HDL levels (0.90 [0.40] vs. 
1.70 [0.80] mmol/l; p<0.0005) compared with the control group. 
The control group included no diabetic subjects whilst the HT 
group contained 20 type 2 diabetic subjects and one subject with 
impaired fasting glucose (IFG). The diabetic and IFG subjects were 
combined (dysglycaemic group) and lipid levels compared with 
the non-diabetic, HT subjects. The dysglycaemic group had higher 
fasting triglyceride (15.1 [26.8] vs. 8.55 [10.8] mmol/l; p<0.005) 
and total cholesterol (8.50 [5.11] vs. 7.70 [3.44] mmol/l; p=0.058) 
levels compared to the non-diabetic subjects, whilst HDL levels 
(0.90 [0.20] vs. 0.90 [0.60] mmol/l; p=0.72) did not signifi cantly 
differ. 
Table 1 shows data for lipid levels in control and HT subjects 
within each ethnic group. In all 3 groups’ triglyceride and choles-
terol levels were signifi cantly higher whilst HDL levels were lower 
in HT than control subjects. Triglyceride levels were signifi cantly 
higher (p<0.05) in the European than the African control group 
whilst cholesterol levels were signifi cantly higher in Indian (p<0.05) 
and European (p<0.005) than African control subjects. 
Genotype and allele frequencies
No difference was found for genotypic or allelic frequencies of 
the C-482T polymorphism between HT and control subjects 
within each ethnic group or when all ethnic groups were com-
bined. Thus, the frequency of the T allele was 0.49 in control 
subjects and 0.44 in HT patients (p=0.44) when the ethnic groups 
were combined. Similar results were found for the T-455C 
polymorphism with the frequency of the C allele being 0.58 in 
control subjects and 0.48 in HT subjects (p=0.13). Therefore the 
control and HT groups were combined when comparing geno-
typic and allelic frequencies across the 3 ethnic groups.
The frequencies of the apoCIII C-482T genotypes for the different 
ethnic groups are shown in Figure 1. The CC genotype was 
signifi cantly rarer in the African population compared to both 
the European (p<0.0005) and the Indian (p<0.05) subject groups 
whilst the TT genotype was more common in African than Indian 
(p<0.005) and European (p<0.005) subjects. The CT genotype was 
more common in Indian than European subjects (p<0.05). The 
T allele frequency was 0.77 in Africans, 0.44 in Indians (p<0.005 
vs. Africans) and 0.36 in Europeans (p<0.0005 vs. Africans).
The frequencies of the apoCIII T-455C genotypes for the 3 ethnic 
groups are shown in Figure 2. The TT genotype was signifi cantly 
more frequent in European than both African (p<0.005) and 
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TABLE 1:  Serum lipid levels in control and hypertriglyceridaemic (HT) subjects within each ethnic group
Data expressed as median [interquartile range].  *p<0.05,  **p<0.005,  ***p<0.0005 vs. control of same ethnic group; †p<0.05, ††p<0.005 vs. African controls.
 Controls HT Controls HT   Controls HT 
N number 14 10 21 57 21 4
Triglyceride  0.95 [1.19] 6.45 [11.0]* 0.90 [0.40]† 10.8 [11.3]*** 0.60 [1.60] 18.8 [18.7]***
Cholesterol  4.56 [0.60]† 7.89 [3.20]* 4.90 [1.10]†† 8.20 [3.50]*** 4.30 [1.40] 10.3 [9.40]*
HDL 1.60 [0.64] 0.91 [0.40] 1.50 [0.40] 0.90 [0.41]** 1.40 [0.60] 0.55 [0.72]*



















Indian (p<0.05) subjects, whilst the CC genotype was more 
common in African than both Indian (p<0.05) and European 
(p<0.005) subjects. The TC genotype was more common in 
Indian than both African (p=0.06) and European (p<0.05) 
subjects. The C allele frequency was 0.79 in African subjects, 0.56 
in Indian subjects (p<0.05 vs. Africans) and 0.41 in European 
subjects (p<0.0005 vs. Africans).
Triglyceride levels across genotypes
The data in Table 2 shows that at both the -482 and -455 loci of 
the apoCIII gene there was no signifi cant variation in triglyceride 
levels with genotype. Thus, for the C-482T polymorphism 
ANCOVA gave a p-value of 0.10 in the control group and 
p=0.51 in the HT subjects and with the T-455C polymorphism, 
p=0.15 in the control group and p=0.81 in the HT group. 
Furthermore, neither total cholesterol nor HDL serum levels 
varied across the genotypes at either locus. If triglyceride levels 
were compared between the homozygous form of the unfavour-
able allele at each loci and the other two genotypes combined 
i.e. TT versus CT+CC at -482 and CC versus CT+TT at -455, 
no signifi cant differences in triglyceride, total cholesterol or HDL 

















FIGURE 1: The percentage prevalence of the apoCIII C-482T 
genotypes in the Indian, European and African subjects. 
Indian      European             African
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FIGURE 2: The percentage prevalence of the apoCIII T-455C 
genotypes in the Indian, European and African subjects. 
Indian      European             African
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TABLE 2:  Triglyceride concentrations across genotypes at the C-482T and T-455C loci of the apoCIII gene in control and hypertriglyceridaemic 
(HT) subjects. 
Data is expressed as median [interquartile range] and units are mmol/l.
 C-482T T-455C C-482T T-455C
Genotypes Control subjects  HT subjects
CC 1.03 [0.55] 0.80 [0.65] 11.1 [9.85] 10.5 [15.4]
 N=16 N=19 N=28 N=20
CT 0.76 [0.50] 0.75 [0.57] 9.00 [13.0] 6.20 [32.1]
 N=22 N=22 N=22 N=23
TT 0.80 [0.70] 1.00 [0.51] 13.1 [16.3] 11.1 [9.64]
 N=15 N=11 N=18 N=24
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DISCUSSION                                                                         
The present study is the fi rst to describe and compare the allelic 
frequencies for the apoCIII T-455C and C-482T polymorphisms in 
South African subjects of European, Indian and African ancestry. 
The results of this study clearly show that allelic and genotypic 
frequencies at the polymorphic -482 and -455 loci of the apoCIII 
gene differ across ethnic groups. This fi nding is supported by data 
from a previous study by Waterworth et al.(18) demonstrating 
that the allelic frequencies of the C-482T polymorphism differs 
between European, South-Asian and Afro-Caribbean/West 
African subjects resident in the UK. That study gave very similar 
allelic frequencies for the C-482T polymorphism to those des-
cribed in the current study however, the T-455C polymorphism 
was not analysed.(18) The allelic frequencies observed for the C-
482T and T-455C polymorphisms for the European population in 
the current paper are also very similar to those reported previously 
for a Dutch population.(19) 
The two apoCIII gene promoter polymorphisms examined in this 
study lie within an insulin response element (IRE). An in vitro 
study has shown that the presence of the T allele at locus -482 
and the C allele at locus -455 led to attenuation of the ability of 
insulin to down-regulate apoCIII gene transcription.(20) It has 
therefore been hypothesised that the polymorphisms in the IRE 
of the apoCIII gene lead to elevated serum triglyceride levels 
by reducing the ability of insulin to down regulate apoCIII gene 
transcription, in vivo. It is also known that transcription of the 
apoCIII gene can be increased by TGF- and reduced by TNF- 
and IL1-.21 Furthermore, the intra-cellular kinase, AMP-acti-
vated protein kinase (AMPK) can decrease hepatic apoCIII 
transcription by reducing cellular levels of the transcription factor, 
HNF-4.(22) This is intriguing because the anti-diabetic agent 
metformin is known to activate AMPK in hepatocytes.(23)
No differences were detected in fasting triglyceride, total choles-
terol or HDL levels across the genotypes at either apoCIII locus. 
This is in contrast to other publications where an association 
has been observed of raised serum triglycerides levels with the 
-482T and -455C alleles.(5,11,13,18) However, there are studies that 
failed to show such associations.(24-26) The present study was also 
unable to fi nd differences in allelic frequencies at either locus 
between hypertriglyceridaemic and control subjects, again sug-
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gesting that neither of these polymorphisms play a prime role in 
determining fasting triglyceride levels. This is further confi rmed by 
the fi nding that the unfavourable -482T and -455C alleles were 
more frequent in African subjects than either of the other two 
population groups even though fasting triglyceride levels were 
lower in African compared to the Indian and European subject 
groups. Previous South African studies have also shown lower 
fasting triglyceride levels in African compared to Indian or Euro-
pean subjects.(14,15)
The polymorphisms in the apoCIII gene that were investigated in 
the present study do not cause any change in function of the 
lipoprotein but rather change its level of expression(20) as shown 
by the higher levels of serum apoCIII in subjects carrying the 
T-455C variant.(5) Thus, the phenotype associated with such a 
polymorphism will not be as marked as that seen when the 
genetic change causes a complete loss of function of the associ-
ated peptide. These small changes in phenotype make the detec-
tion of an association between such polymorphisms and the 
phenotype more diffi cult to observe and may explain why our 
study and others have found no link between the apoCIII 
polymorphisms and fasting serum triglyceride levels.(24-26)
It is also possible that no association was found between serum 
triglyceride levels and the genotypes at either apoCIII locus 
because of the low n number of study subjects. Furthermore, 
other genetic polymorphisms and a variety of environmental, 
anthropometric, ethnic and demographic factors are known to 
infl uence triglyceride metabolism(27) and such factors may ‘drown 
out’ the infl uence of the apoCIII polymorphisms in the present 
investigation, especially with a small study cohort. Also, the 
selection criteria for hypertriglyceridaemia used in the current 
study i.e. > 3mmol/l may have led to the inclusion of subjects 
with a wide array of different disease aetiologies including simple 
obesity, type 2 diabetes and other genetic forms of hyper-
triglyceridaemia. Thus, identifi cation of the specifi c effect of the 
apoCIII gene polymorphisms on fasting triglyceride levels within this 
cohort may have been obscured.
A major drawback of the current investigation is that body mass 
index (BMI) was not measured in the study participants. BMI is 



















fore it is possible that the lack of association between the apoCIII 
promoter polymorphisms and serum triglyceride levels is due to 
differences in BMI across the genotypes. However, one study has 
shown that the apoCIII C-482T polymorphism has no relation-
ship with BMI in European and South Asian subjects but does in a 
mixed group of Afro-Caribbean/West African subjects where 
BMI was higher in the presence of the -482T allele.(18) However, 
adjusting for BMI had minimal effects on the statistical outcomes 
for the relationship between the C-482T genotype and trigly-
ceride levels, in any of the 3 ethnic groups.(18)
The current study was unable to show associations between 
either apoCIII polymorphism and lipid levels. This may be a result 
of the low n number. However, the study was suffi ciently powered 
to demonstrate ethnic differences in allele frequencies at both 
loci and also to show ethnic differences in fasting serum lipid 
levels. Thus, it is possible to conclude that neither of the apoCIII 
polymorphisms can explain ethnic differences in lipid levels but 
we cannot rule out the possibility that within each ethnic group 
these polymorphisms may play a role in infl uencing lipid 
metabolism. 
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